Watch For Duplications on Discharge Med Lists With Soliqua and Lantus
January 2017
Adlyxin (ad-LIKS-in) and Soliqua (soh-LEE-kwa) will be two new once-daily injectable meds for type 2 diabetes...and more are coming.
Lixisenatide (Adlyxin) is the sixth GLP-1 agonist for diabetes. Think of it as similar to Byetta...but it's once-daily instead of BID.
Soliqua is the first insulin/GLP-1 agonist combo to hit the market. It contains insulin glargine U-100 (Lantus) plus lixisenatide.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote